JAK2 V617F mutation and association with clinical indices in patients with myeloproliferative neoplasm:analysis of 110 cases

Objective:To analyze the JAK2 V617F mutation in 110 patients with myeloproliferative neoplasm(MPN) and the correlation with clinical characteristics.Methods:We collected the bone marrow specimens derived from 110 patients with MPN who were admitted to Hunan People' s Hospital between September 2011 and July 2012 and to three miscellaneous hospitals between January and October 2012.Of these cases,44 had polycythemia vera(PV),55 essential thrombocythemia(ET) and 11 primary myelofibrosis(PMF).Two healthy subjects who took consent to donate bone marrow served as the blank controls.Bone marrow specimens were subject to polymerase chain reaction for gene amplification and gene sequencing for assessment of JAK2 V617F mutation.This entailed the analysis on the correlation with sex,subtype of MPN,age and peripheral blood hemoglobin(Hb),white blood cell(WBC) and platelet(PLT) count.Results:Of the110 patients recruited,MPN yielded a positive rate of 67.27%for JAK2 V617F mutation,the incidence of which was 70.45%(31/44),71.4%(39/55) and 30%(4/11) for PV,ET and PMF,respectively.Compared with patients with wildtype genotypes,those with PV who had JAK2 V617F mutations were associated with increased WBC and PLT counts.Patients with ET who had JAK2V 617F mutants were of advanced age and yielded higher WBC count and Hb.In addition,patients with PMF who had JAK2 V617F mutants presented with increased peripheral blood Hb compared with those who had wildtype genotypes.Conclusion;In patients with MPN,the JAK2 V617F mutation is associated with the age of onset and hematological indices.